Effects of Arsenic on Keratinocytes in a Skin Equivalent Model

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2004 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00166946
First received: September 12, 2005
Last updated: December 20, 2005
Last verified: November 2004
  Purpose

We popose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen’s disease.


Condition Intervention
Bowen Disease
Procedure: foreskin from healthy adults for organotypic culture

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
Official Title: Effects of Arsenic on Keratinocytes in a Skin Equivalent Model

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • we collect foreskin from healthy adults

Estimated Enrollment: 20
Study Start Date: June 2005
Estimated Study Completion Date: January 2008
Detailed Description:

Arsenical cancers (comprising skin, bladder, kidney, lung, colon and liver malignancies) were prevalent in southwestern coast of Taiwan where the artesian water was contaminated with high concentration of arsenic. Skin is a main target of arsenical poisoning. The cutaneous manifestations of chronic arsenism can take form as hyperpigmentation, hypopigmentation, arsenical keratosis and arsenical skin cancers. The most popular arsenical skin cancer is Bowen’s disease, which is a carcinoma in situ of skin and often confined to sun-protected skin. Pathologically, there are several characteristics present in Bowen’s disease: (1) abnormal cell proliferation and carcinogenesis in keratinocytes; (2) dysplasia and apoptosis at the lesion; (3) integrin deficiency/defect in the basal cells of the skin; (4) dysfunctions in peripheral immune cells. Our pervious results indicated that arsenic affected cell cycle regulation by influencing the proliferation and apoptosis of keratinocytes. Furthermore, we found that integrins were deficient in basal layer of lesional and perilesional sites of Bowen’s disease as demonstrated by immunohistochemistry. The integrin deficiency in Bowen’s disease might lead to abnormality of cell cycle regulation, differentiation and carcinogenesis. In addition, arsenic can destruct lymphocytes to cytokine regulation and induce lymphocytes apoptosis. We propose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen’s disease. There are many regulatory mechanisms involved in progression of chemical carcinogenesis, including the reactions among carcinogen and target cells, supporting cells and immune interactions. Therefore, this study is to investigate these skin cell-cell interactions induced by arsenic using an organotypic epidermis culture model. By using this model, we can mimic the mechanism of arsenic-induced skin diseases. Which will give us much more information that similar to carcinogenesis progesee in human body as compared to cell culture model. The effects of arsenic on epidermis formation, the effects of UVB and arsenic on arsenical carcinogenesis and the interactions between immune cells and skin cells will be studied in this 3-year proposal as described below:

The 1st year: Study of arsenical effects on integrin expression, cell proliferation, differentiation and apoptosis in organotypic epidermis.

The 2nd year: Study of arsenic and/or UVB –induced biological changes in organotypic epidermis and Bowen’s disease.

The 3rd year: Study of the interactions between immune cells and epidermal cells induced by arsenic.

This study will give us much more information that similar to carcinogenesis progesee in human body as compaired to cell culture model. We hope the result of this study can provide a useful model in chemical carcinogenesis investigation field.

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Normal healthy adult -

Exclusion Criteria:

systemic disease or with a history of exposure to arsenic-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166946

Contacts
Contact: Hsin-Su Yu, MD PHD 886-2-23562141 dermyu@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Suspended
Taipei, Taiwan, Province of China, Taiwan, 100
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Hsin-Su Yu, MD PHD    886-2-23562141    dermyu@ha.mc.ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Director: Hsin-Su Yu, MD PHD National Taiwan Univesity Hospital, Dept. of Dermatology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00166946     History of Changes
Other Study ID Numbers: 9361701179
Study First Received: September 12, 2005
Last Updated: December 20, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Bowen's Disease
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell

ClinicalTrials.gov processed this record on July 22, 2014